Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanobiotix reports 'proof of concept for its nanoparticles in treating glioblastoma multiforme (brain cancer)

Abstract:
Preclinical results demonstrate that the Company's nanoparticles-nanoPDT- selectively target tumor tissues and destroy them after activation by a laser.

Study, co-funded by Nanobiotix and Cancéropôle Lyon Auvergne Rhône-Alpes ('CLARA'), was conducted by the French National Institute for Health and Medical Research ('INSERM') under principal investigator and neuro-oncologist Prof. and Med. dr. Jérôme Honnorat.

Nanobiotix reports 'proof of concept for its nanoparticles in treating glioblastoma multiforme (brain cancer)

Paris | Posted on April 6th, 2009

Nanobiotix, an emerging nanomedicine company, announced today that an independent preclinical study has validated the applicability of using its nanoparticles-nanoPDT-to treat glioblastoma multiforme, one of the most prevalent brain tumors. Nanobiotix expects to attract corporate partners for the development of nanoPDT as the Company focuses development efforts on its nanoXray technology.

Co-funded by Nanobiotix and Cancéropôle Lyon Auvergne Rhône-Alpes ('CLARA'), the 'proof-of-concept' preclinical study was conducted by the French National Institute for Health and Medical Research ('INSERM') under principal investigator and neuro-oncologist Prof. and Med. dr. Jérôme Honnorat.

"Our nanotechnology is designed to allow for the precise destruction of cancer cells via the controlled application of an outside-the-body energy source-in this case, a laser beam. Of course, there is much more work to be done, but we are extremely encouraged by these preclinical findings, which dramatically demonstrate the therapeutic effect of nanoparticles on glioblastoma and open the possibility of a new weapon with which neuro-oncologists might fight this difficult-to-treat tumor," said Laurent Lévy, Ph.D., President and CEO of Nanobiotix and Co-President of the French Technology Platform on Nanotechnology (FTPN).

"The nanoPDT particles allow for the controlled generation of physical reactions in targeted cells when triggered by the application of an external energy source-a laser beam in this case. This may have significant ramifications for cancer therapy in the not-too-distant future," added Paras N. Prasad, Ph.D., one of the world's leading authorities on nanotechnology and one of the inventors of the Nanobiotix technology. Dr. Prasad is a co-founder of Nanobiotix and Executive Director of the Institute for Lasers, Photonics and Biophotonics at SUNY (Buffalo).

####

About Nanobiotix
Nanobiotix is an emerging nanomedicine company combining dramatic advances in nanotechnology and molecular biology to develop nanoXray™- a technology platform that is expected to be turned 'on' and 'off' outside the body to selectively treat a variety of cancers safely and noninvasively. Use of nanoXray is intended to resolve radiation therapy's biggest drawback: destruction of healthy tissue and its subsequent deleterious side effects when a high dose of Xray is necessary. The core of a nanoXray nanoparticle is an inactive and inert substance-not a drug-that can be activated to locally (intratumor) increase the dose of Xray, which is then expected to lead to higher efficiency. After nanoXray nanoparticles accumulate in the target tissues, a standard X-ray is applied that is intended to generate a local therapeutic effect, designed to destroy only the targeted tumor cells. This mechanism suggests total control of the intended therapeutic effect.

For more information, please click here

Contacts:
Ronald Trahan, APR
Ronald Trahan Associates Inc.
508-359-4005, x108

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Leti IEDM 2016 Paper Clarifies Correlation between Endurance, Window Margin and Retention in RRAM for First Time: Paper Presented at IEDM 2016 Offers Ways to Reconcile High-cycling Requirements and Instability at High Temperatures in Resistive RAM December 6th, 2016

Tokyo Institute of Technology research: 3D solutions to energy savings in silicon power transistors December 6th, 2016

Physicists decipher electronic properties of materials in work that may change transistors December 6th, 2016

Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016

Possible Futures

Physicists decipher electronic properties of materials in work that may change transistors December 6th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Construction of practical quantum computers radically simplified: Scientists invent ground-breaking new method that puts quantum computers within reach December 5th, 2016

Shape matters when light meets atom: Mapping the interaction of a single atom with a single photon may inform design of quantum devices December 4th, 2016

Nanomedicine

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

Announcements

Leti IEDM 2016 Paper Clarifies Correlation between Endurance, Window Margin and Retention in RRAM for First Time: Paper Presented at IEDM 2016 Offers Ways to Reconcile High-cycling Requirements and Instability at High Temperatures in Resistive RAM December 6th, 2016

Tokyo Institute of Technology research: 3D solutions to energy savings in silicon power transistors December 6th, 2016

Physicists decipher electronic properties of materials in work that may change transistors December 6th, 2016

Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016

Nanobiotechnology

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

From champagne bubbles, dance parties and disease to new nanomaterials: Understanding nucleation of protein filaments might help with Alzheimer's Disease and type 2 Diabetes November 24th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project